Biosimilars Market Role in Reducing Healthcare Costs and …
Dec 9, 2024 · The global biosimilars market is witnessing remarkable growth, driven by factors such as cost efficiency, increased demand for accessible healthcare solutions, and the expiration of patents for branded biologic drugs. With a market that was valued at approximately USD 20.4 billion in 2021, the biosimilars market is expected to expand significantly, reaching more than USD 85 billion by the end ...
Top 12 Clinical Research Organisations (CROs) in 2023
Feb 23, 2023 · The global clinical trials market was estimated to be worth $38.7 billion in 2021 and is expected to reach £52 billion by 2026. In this article, we look at the top 12 CROs in the world, highlighting the companies driving this considerable growth and accelerating research and development across the globe.. ICON. Recognised as the world’s largest and most comprehensive CRO powered by ...
PharmiWeb.com: The Heart of Life Sciences on the Web
PharmiWeb.com - Global pharma news from the pharmaceutical industry, biotech, clinical research, life science & healthcare. Pharma Events Listings, Pharma Company Directory & pharma jobs.
Ottimo Pharma Emerges from Stealth with Backing from Medicxi …
Oct 28, 2024 · · David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer · Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer · James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair [28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, a private biotech company ...
PLL Therapeutics obtains authorization to start phase I/II trial in ...
Nov 19, 2024 · Australia’s Human Research Ethics Committees (HREC) cleared first-in-human study of drug candidate PLL001PLL001 aims at restoring microbiome and stopping gut from leaking to treat root cause of ALS, not solely symptomsLead candidate stems from PLL Therapeutics’ polypeptide delivery platform, early-diagnostics and po...
Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s …
16.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
Nyxoah Announces Commercial Launch of Genio® Innovative …
Dec 13, 2024 · EQS-News: Nyxoah SA. / Key word(s): Market LaunchNyxoah Announces Commercial Launch of Genio® Innovative Therapy in England 13.12.2024 / 08:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implant...
Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce …
Dec 13, 2024 · EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): AgreementNewron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories 13.12.2024 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Newron and EA Pharma (a...
Sanofi launches high-dose egg-based quadrivalent influenza …
Oct 15, 2024 · Sanofi launches high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK · Developed with a higher antigen content to increase protection in older adults, a population at greater risk of severe complications from infection.· ...
iiCON supports new phase II trial of novel pneumococcal vaccine ...
Nov 25, 2024 · iiCON supports new phase II trial of novel pneumococcal vaccine, PnuBioVax. The Infection Innovation Consortium: iiCON is managing a new £3.2 million Medical Research Council funded trial to enable progress into development of a new vaccine against pneumococcal disease, which has high rates of antibiotic resistance, and is a major cause of disease worldwide.